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PI3Kd inhibition reduces TNF secretion and
neuroinflammation in a mouse cerebral stroke
model
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Stroke is a major cause of death worldwide and the leading cause of permanent disability.
Although reperfusion is currently used as treatment, the restoration of blood flow following
ischaemia elicits a profound inflammatory response mediated by proinflammatory cytokines
such as tumour necrosis factor (TNF), exacerbating tissue damage and worsening the
outcomes for stroke patients. Phosphoinositide 3-kinase delta (PI3Kd) controls intracellular
TNF trafficking in macrophages and therefore represents a prospective target to limit
neuroinflammation. Here we show that PI3Kd inhibition confers protection in ischaemia/
reperfusion models of stroke. In vitro, restoration of glucose supply following an episode of
glucose deprivation potentiates TNF secretion from primary microglia—an effect that
is sensitive to PI3Kd inhibition. In vivo, transient middle cerebral artery occlusion and
reperfusion in kinase-dead PI3Kd (p110dD910A/D910A) or wild-type mice pre- or post-treated
with the PI3Kd inhibitor CAL-101, leads to reduced TNF levels, decreased leukocyte
infiltration, reduced infarct size and improved functional outcome. These data identify PI3Kd
as a potential therapeutic target in ischaemic stroke.
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A
cute occlusion of the cerebral arteries results in immediate
loss of oxygen and glucose to the core region of the
affected brain tissue. A series of ischaemic cascades is
rapidly activated, interfering with endogenous repair mechanisms
of the ischaemic brain tissue. To date, there are only three
recommended treatments for acute ischaemic stroke—
plasminogen activator, aspirin and stroke unit, of which only
plasminogen activator restores the blood flow by promoting
reperfusion1. However, reperfusion is also associated with a
strong inflammatory response mediated by proinflammatory
cytokines such as tumour necrosis factor a (TNF)2–5. This release
of cytokines is accompanied by activation of glial cells, vascular
endothelial activation, leukocyte infiltration and neuronal
apoptosis5–7. Inflammation contributes to tissue damage8 and
has been linked to a worsening of clinical outcomes9,10. TNF
antagonists, which block both soluble and membrane-bound
biologically active TNF, have therefore been tested in stroke,
albeit with limited success7,11–12.
Although the inflammatory response is regarded as harmful in
stroke, a low, basal level of TNF in the central nervous system
(CNS) is also important for neuronal survival6,13. Furthermore,
strategies aimed at eliminating the soluble form of TNF using
inhibitors of TNF-converting enzyme suffer from a lack of
specificity14. Directly blocking the release of pathogenic TNF,
while maintaining homoeostatic pools of TNF, may thus be more
effective when aiming to attenuate neuroinflammation following
reperfusion therapy in stroke. Phosphoinositide 3-kinase delta
(PI3Kd) regulates inflammatory and oncological processes, and
PI3Kd inhibitors are being explored clinically as pharmacological
treatments for inflammatory disease and cancer15. PI3Kd
inhibitors have shown remarkable therapeutic impact on phase
III (ref. 16) trials in chronic lymphocytic leukaemia and non-
Hodgkin’s lymphoma16,17. We have recently shown that PI3Kd
activity regulates post-Golgi transport and secretion of TNF in
macrophages18,19. PI3Kd is similarly implicated in the release of
cytokines from other immune cells20–24, and PI3Kd-selective
inhibitors have significant anti-inflammatory efficacy24–26. A dual
PI3Kg/d inhibitor has been shown to reduce damage in
myocardial infarction27. However, despite its putative key role
in post-ischaemic inflammation, PI3Kd has not yet been studied
in the context of stroke.
Our study highlights a novel role for PI3Kd in stroke-induced
injury. Our results show that PI3Kd regulates TNF secretion from
primary microglia as PI3Kd inhibition dampens TNF release
induced by a protocol of glucose deprivation (GD)/restoration
in vitro. Besides, genetic or pharmacological inactivation of PI3Kd
improves ischaemic outcomes in mice, reduces TNF in microglia
as early as 3 h post ischaemia and impairs leukocyte recruitment
to the injured hemisphere. Our results demonstrate that
inactivation of PI3Kd in the brain, and not in the peripheral
immune system, is the key initiator of these protective effects.
Results
PI3Kd mediates TNF secretion in primary microglia. In vitro,
PI3Kd is not detectable by immunocytochemistry in astrocytes
but is present in neurons28 and microglia in which it appears
concentrated at the perinuclear Golgi18 (Fig. 1a). To identify the
principal TNF producers in the brain, we measured TNF
secretion from primary microglia, astrocytes and neurons in
response to GD, which mimics the hypoglycaemic conditions
during stroke29; treatment with lipopolysaccharide (LPS), the
prototypical activator of TNF secretion in vitro; or a combination
of both treatments. No significant TNF release was detected in
astrocytes or neurons. In contrast, microglia secreted high levels
of TNF in response to LPS and to a lesser extent in response to
GD (Fig. 1b). In keeping with our previous study in
macrophages18, microglia from PI3Kd kinase-inactive
(p110dD910A/D910A)30 mice secreted significantly less TNF in
response to LPS than wild-type controls (Fig. 2a,b). Similar
observations were made in microglia from wild-type mice that
were treated ex vivo with the PI3Kd-selective inhibitor IC87114
(ref. 18) or CAL-101 (ref. 23), the latter being a highly specific
inhibitor that is 40- to 300-fold more selective for PI3Kd than
other PI3K class I enzymes31 (Fig. 2a,b). Intriguingly, GD
dramatically reduced LPS-induced TNF secretion from microglia
(Fig. 1b), suggesting that glucose removal might impair PI3Kd-
sensitive TNF biosynthesis and/or secretion by these cells
(Fig. 2c,d). To test this hypothesis, we mimicked the paradigm
of reperfusion after stroke by replacing the glucose-free medium
with normal glucose-containing culture medium following 1 h
GD. Such glucose restoration following 1 h of GD significantly
increased TNF secretion, an effect that could be blocked by PI3Kd
inhibition (Fig. 3a). Using an assay to assess the intracellular
trafficking of TNF18,32, we found that TNF surface delivery was
enhanced under conditions of glucose restoration, in a PI3Kd-
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Figure 1 | PI3Kd expression and TNF secretion from cortical brain cells.
(a) PI3Kd (green) distributed diffusely through the cytoplasm and in the
Golgi region in neurons (bIII-tubulin; red) and microglia (Iba1; red). Little or
no PI3Kd labelling (green channel) was seen in astrocytes (GFAP; red
channel). Scale bar, 10mm. (b) Primary microglia secrete TNF in response to
100 ngml 1 LPS or glucose deprivation (GD). GD or LPS treatment were
for 6 h. Data are means±s.e.m., n¼4 cultures. *Po0.05; ***Po0.001;
two-tailed Student’s t-test.
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sensitive manner (Fig. 3b). Intracellular TNF levels remained
unchanged after 1 h of GD (followed by 5 h glucose restoration)
in p110dD910A/D910A-derived or CAL-101-treated wild-type
microglia (Fig. 3c), suggesting that the de novo synthesis of
TNF was not altered. Taken together, these data demonstrate that
PI3Kd activity is required for TNF trafficking and secretion on
glucose restoration following GD in microglia.
PI3Kd inhibition protects from ischaemia. To recapitulate
reperfusion in ischaemic stroke in vivo, we induced transient
middle cerebral artery occlusion (tMCAO)28,33–35 in wild-type
and p110dD910A/D910A mice, followed by 24–72 h reperfusion
(Fig. 4a–c). The extent of brain damage and neurological deficit
measured 72 h after ischaemia/reperfusion (I/R) was significantly
lower in p110dD910A/D910A mice than in wild-type mice.
Similarly, a single intravenous dose of 40mg kg 1 of CAL-101,
given 15min before ischaemia in wild-type mice (pre-treatment),
significantly reduced infarction after 72 h (Fig. 4d,e). However,
lower doses (20, 10 and 1mg kg 1) did not achieve significant
protection (Fig. 4e). Importantly, even when given 3 h after the
onset of reperfusion (post-treatment), a dose of 40mg CAL-101
per kg body weight was still effective in reducing the infarct
volume by an average of 44% compared with the vehicle-treated
control group. Pre- or post-treatment (3 h) with CAL-101 also
consistently improved neurological scores following tMCAO
(Fig. 4f). The benefits of CAL-101 treatment on stroke outcomes
were no longer evident if the drug was administered 6 h after I/R,
with infarct sizes not significantly different from those observed
in vehicle-treated mice (44.05±4.16% versus 45.91±4.30%,
respectively, n¼ 6). PI3Kd inhibition thus protects against
reperfusion-induced damage in the brain for up to at least 3 h
after an ischaemic insult.
We next employed liquid chromatography–electrospray
ionization–mass spectrometry to quantitatively assess exposure
of the brain to CAL-101 following peripheral (intravenous)
injection (Fig. 4g). Low levels of CAL-101 could be detected in the
brains of sham-operated mice, indicating some ability of the
inhibitor to cross the blood–brain barrier. Importantly, CAL-101
levels within the brain were significantly increased 24 h after
tMCAO, demonstrating increased penetration and exposure to
CAL-101 as a result of I/R-associated blood-brain barrier
breakdown.
Having established the benefits of PI3Kd inhibition in
ischaemic stroke, we next tested whether these protective effects
could be related, at least in part, to a reduction in TNF following
I/R in vivo. Brains were recovered 24 h after I/R and homogenized
hemispheres were analysed for total TNF levels by western
blotting. In wild-type control mice with tMCAO, high levels of
TNF could be detected in the ipsilateral hemisphere and, to
varying degrees, the contralateral hemisphere, consistent with
bilateral inflammation following I/R (Fig. 4h,i). In contrast, TNF
levels were significantly lower in both hemispheres in
p110dD910A/D910A and CAL-101 pre- or post-treated mice
(Fig. 4h, full blots in Supplementary Fig. 1).
PI3Kd inhibition reduces TNF in Iba1-positive brain cells. We
next used TNF and Iba1 immunohistochemistry to monitor TNF
expression in microglia/macrophages at the infarct site and other
regions of the brain. The infarct core was defined as the region
where microtubule-associated protein-2 (MAP-2) was absent36
and the penumbra as the MAP-2-positive region that was less
than 1mm away from the infarct core. The equivalent
contralateral region was also examined. At 24 h after I/R, TNF
was detected in Iba1-positive cells (Fig. 5a–d) and, to lesser
extent, in glial fibrillary acidic protein (GFAP)-positive astrocytes
(Fig. 6a–d). Co-localization between TNF and Iba1 or GFAP was
analysed using Imaris software to derive Pearson’s correlation
coefficients (r)37,38. In brain slices from wild-type mice after I/R,
co-labelled Iba1/TNF-positive cells were particularly abundant in
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Figure 2 | Effects of PI3Kd inhibitors on TNF secretion from LPS-
stimulated or glucose-deprived microglia. TNF secretion from wild-type or
p110dD910A/D910A primary microglia cultures in response to 100ngml 1
LPS stimulation (a) or GD (b) over a 10-h time course. TNF secretion from
wild-type microglia cultures after LPS stimulation (b) or GD (d) in the
continuous presence of vehicle dimethylsulphoxide (DMSO), CAL-101 or
IC871184 at the indicated concentrations. Data (a–d) are means±s.e.m.,
n¼ 3 cultures. *Po0.05; **Po0.01; two-tailed Student’s t-test.
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the ischaemic penumbra (Fig. 5a,c; Supplementary Movie 1),
consistent with the high inflammatory activity in this region39. In
slices from p110dD910A/D910A mice or CAL-101 pre-treated mice
after I/R, the correlation coefficient of Iba1/TNF-positive cells was
significantly reduced by, on average, 73% in the penumbra and
69% in the contralateral areas. Importantly, slices from wild-type
mice treated with CAL-101 3 h after onset of reperfusion
also still exhibited a significant reduction in Iba1/TNF-positive
cells in both the penumbra and contralateral areas (Fig. 5c,d;
Supplementary Movie 2). These results confirm that PI3Kd
inhibition reduces overall TNF immunoreactivity in Iba1-positive
cells in regions both proximal and distal to the infarct core. We
also observed fewer GFAP-positive astrocytes that were also
positive for TNF in p110dD910A/D910A mice and CAL-101 pre- or
post-treated mice (Fig. 6b,d; Supplementary Movies 3,4). The fact
that PI3Kd could not be detected in astrocytes in vitro (Fig. 1a)
may indicate that it does not regulate TNF trafficking in this glial
cell type. Lastly, in addition to TNF, other inflammatory
cytokines such as the interleukins IL-6 and IL-1b were also
decreased in the brains of PI3Kd mice after I/R (Fig. 7, full blots
in Supplementary Fig. 1). To better appreciate the role of PI3Kd
in inflammatory signalling during the very early phases post
ischaemia, we carried out a similar analysis of TNF
immunoreactivity at 3 and 12 h post I/R in wild-type and
p110dD910A/D910A mice. At these early time points, the vast
majority of Iba1-positive cells are of microglial origin as
peripheral inflammatory cells have not yet invaded the brain
parenchyma40. Importantly, as early as 3 h post reperfusion, the
high level of co-localization that is normally detected between
TNF and Iba1 in activated microglia/macrophages from the
ipsilateral I/R side of the wild-type animals was significantly
reduced in the same region of the p110dD910A/D910A mice
(Fig. 5e). Similar observations were made at 12 h post IR in both
the injured and non-injured hemispheres (Fig. 5f), in good
agreement with a high level of protection being conferred on
these animals. In wild-type mice, TNF immunoreactivity
appeared diffusely throughout the cytoplasm of Iba1-positive
cells (Fig. 5g). In sharp contrast, TNF staining always appeared as
a perinuclear speck within the same cells in the brains of
p110dD910A mice. This observation is consistent with the
hypothesis that PI3Kd prevents the release and/or expression of
inflammatory TNF in Iba1-positive cells18.
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Figure 3 | PI3Kd controls TNF trafficking and release elicited by glucose restoration in glucose-deprived microglia. (a) TNF secretion from wild-type
microglia cultures (n¼ 5–9) subjected to glucose deprivation (GD) for either 1 h (GD1) or 6 h (GD6) followed by replacement with normal culture
medium containing 25mM glucose for another 5 h (N5) in the continuous presence or absence of CAL-101 (1 mM). (b) Addition of the TNF-converting
enzyme (TACE) inhibitor (TAPI), retained TNF at the cell surface for immunostaining (red). Microglia were then permeabilized for intracellular TNF staining
(green). 40 ,6-diamidino-2-phenylindole (DAPI)-stained nuclei are depicted in blue. Scale bar, 20mm. (c) Quantification of surface and intracellular TNF
staining intensity from b, n¼ 18–24 cells. Data (a–c) are means±s.e.m. *Po0.05; **Po0.01; ***Po0.001, two-tailed Student’s t-test.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms4450
4 NATURE COMMUNICATIONS | 5:3450 | DOI: 10.1038/ncomms4450 |www.nature.com/naturecommunications
& 2014 Macmillan Publishers Limited. All rights reserved.
DMSO
WT
Time (h)
a b c
d e
Sham
WT
p110δD910A
***
***
Sham
DMSO
CAL-101 pre
CAL-101 post
**
CAL-101
pre
CAL-101
post
CA
L-
10
1 
(nM
 in
 pl
as
ma
)
g
f
CAL-101
0.0
0.2
0.4
0.6
DMSO
CAL-101 pre
CAL-101 post
To
ta
l T
N
F
*
*
To
ta
l T
N
F
0
20
40
60
80
α−tubulin
26 TNF
p110δD910AWT
**
*
24 48 72
Co
ntr
a
Ips
i
Co
ntr
a
Ips
i
Co
ntr
a
Ips
i
h i
Co
ntr
a
Ips
i
Co
ntr
a
Ips
i
kDa
52
Co
ntr
a
Ips
i
Ips
i
Co
ntr
a
Co
ntr
a
Ips
i
Co
ntr
a
Ips
i
Co
ntr
a
Ips
i
WT
p110δD910A
*
In
fa
rc
t v
o
lu
m
e 
(%
)
0
20
40
60
Sh
am
WT
 I/R
p1
10
δD
91
0A  
I/R
N
eu
ro
lo
gi
ca
l d
ef
ici
t s
co
re
0
2
4
5
1
3
24 48 72
Time (h)
DMSO
CAL-101
pre
CAL-101
post
N
eu
ro
lo
gi
ca
l d
ef
ici
t s
co
re
0
2
4
5
1
3
Sh
am
DM
SO
40
 m
g k
g–
1  pr
e
40
 m
g k
g–
1  po
st
20
 m
g k
g–
1  po
st
10
 m
g k
g–
1  po
st
1 m
g k
g–
1  po
st
In
fa
rc
t v
o
lu
m
e 
(%
)
**
1 2 3 4 5
0
10
20
30
0
100
1.2
0.9
0.6
0.3
0.0
200
300
CAL-101 (pmol
 g
–1
 in Brain)
p110δD910A
Figure 4 | Genetic or pharmacological inhibition of PI3Kd reduces cerebral infarction and improves neurological outcome in ischaemia/reperfusion
(I/R). Representative images (a) and graph (b) of infarct volume measurements in wild-type (WT) and p110dD910A/D910A mice subjected to transient middle
cerebral artery occlusion (tMCAO) for 1 h followed by 72h reperfusion. Scale bar, 2mm. (c) Neurological scores evaluated at 24, 48 and 72h
(n¼8–23 mice per group) based on a five-point system: 0, no deficit; 1, failure to extend right paw; 2, circling to the right; 3, falling to the right; and 4, unable
to walk spontaneously. (d) Representative images of infarct volumes in wild-type mice treated with vehicle dimethylsulphoxide (DMSO) or CAL-101
(40mgkg 1 i.v.) 15min before ischaemia (Pre) or 3 h after reperfusion (Post). Scale bars, 2mm. (e) Graph depicting infarct volume measurements in wild-
type mice treated i.v. with DMSO or CAL-101 at the indicated concentrations. Infarct volume data are %±s.e.m (relative to total contralateral hemisphere),
n¼ 7–28 mice per group. **Po0.01; ***Po0.001, one-way analysis of variance (ANOVA) and Turkey’s post hoc test. (f) Neurological deficit scores at
indicated times post-tMCAO in wild-type mice treated with DMSO or CAL-101 (40mgkg 1 i.v.) 15min before ischaemia (CAL-101 Pre) or 3 h after
reperfusion (Post). (g) Plasma (nmol l 1) and brain (pmol g 1) concentrations of CAL-101 in mice measured by LC- MS/MS: (1) shamþCAL-101 (plasma),
(2) shamCAL-101 (brain), (3) shamþCAL-101 (brain), (4) I/RþCAL-101 3 h post treatment (perfused brain), (5) I/RþCAL-101 3 h post treatment (non-
perfused brain); data are mean±s.e.m, n¼ 3 mice per group. *Po0.05; **Po0.005. (h) Western blot of the contralateral and ipsilateral hemispheres
of wild-type and p110dD910A/D910A brains after 24h I/R. Densitometric measurements (mean±s.e.m.) of TNF normalized to tubulin, n¼4 mice per group.
*Po0.05; **Po0.01, two-tailed Student’s t-test. (i) Western blot of the contralateral and ipsilateral hemispheres of DMSO- and CAL-101-treated mice after
24h I/R. Densitometric measurements (mean±s.e.m.) of TNF normalized to a-tubulin, n¼4 mice per group. *Po0.05, two-tailed Student’s t-test.
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Brain PI3Kd drives ischaemia-induced leukocyte infiltration.
To assess the effect of PI3Kd genetic inactivation or pharmaco-
logical inhibition on leukocyte infiltration post reperfusion,
analysis of leukocyte populations in the ischaemic hemisphere
was carried out with flow cytometry. Twenty-four hours after I/R,
p110dD910A/D910A mice showed a 58% decrease in CD45high
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Figure 5 | Iba1-positive cells with inactive PI3Kd have reduced TNF immunoreactivity in vivo. Brains from (a) wild-type (WT) or p110dD910A/D910A mice
and (c) wild-type mice treated with vehicle dimethylsulphoxide (DMSO) or CAL-101 (40mg k 1g i.v.) 15min before ischaemia (CAL-101, Pre) or 3 h after
reperfusion (CAL-101, Post) were cryosectioned at 10 mm and analysed for TNF (red) and Iba1 (green) expression in the infarct core, penumbra or
contralateral areas (confocal optical sectioning) at 24 h after I/R; cell nuclei are depicted in white. Scale bar, 15mm. (b,d) Analysis of co-localization of TNF
and Iba1 at 24 h post reperfusion, calculated as Pearson’s correlation coefficient, r, on (b) WTversus p110dD910A/D910A mice and (c) wild-type mice treated
with vehicle DMSO or CAL-101 (40mg kg 1 i.v.). Data are mean values±s.e.m, n¼ 3 mice per group. (e,f) Wild-type and p110dD910A/D910A mice
subjected to transient middle cerebral artery occlusion (tMCAO) for 1 h followed by 3 h (e) to 12 h (f) reperfusion, after which, TNF and Iba1 co-localization
was analysed in the ipsilateral (penumbra) and contralateral regions. *Po0.05; **Po0.01; ***Po0.001, two-tailed Student’s t-test. (g) Confocal
photomicrographs showing a typical Iba1-positive cell in the penumbra of a wild-type and p110dD910A mouse, 3 h after I/R. Note that TNF staining appears
throughout the whole Iba1-positive cell in wild-type mice but only as a speck on the periphery of the nucleus in p110dD910A mice (arrow). Scale bar, 15mm.
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CNS-infiltrating leukocytes in the ipsilesional hemisphere com-
pared with wild-type mice, consistent with reduced inflammation
(Fig. 8a,b). This protective effect was also achieved with a single,
post-treatment dose of CAL-101 administered 3 h after the onset
of reperfusion (Fig. 8d,e), indicating that inhibition of PI3Kd after
reperfusion is effective in controlling the leukocyte influx into the
ischaemic brain. Within the CD45high infiltrating cell population,
we observed a significant reduction in the CD11bþLy6Gþ
neutrophils from brain homogenates of both p110dD910A/D910A
mice and CAL-101 post-treated mice (Fig. 8c,f).
We next tested whether this diminished infiltration resulted
from PI3Kd inactivation in the CNS or in circulating leukocytes.
We used bone marrow (BM) chimera approaches to selectively
introduce the p110dD910A/D910A mutation into the peripheral
immune compartment only, which allowed us to specifically
examine the role of PI3Kd in leukocyte recruitment following
tMCAO. Transplantation of p110dD910A/D910A BM into condi-
tioned Cx3cr1gfp/þ hosts revealed no significant differences in
neutrophil numbers (Ly6B.2þ Iba1GFP cells) within the
infarcted brain tissue at 24 h after I/R compared with controls
that received wild-type BM transplants (Fig. 8g). The use of
Cx3cr1gfp/þ mice as recipient hosts also allowed us to unequi-
vocally distinguish brain microglia (Iba1þGFPþ cells) from
infiltrating donor BM-derived monocytes/macrophages (Iba1þ
GFP cells; Fig. 8i). Taking advantage of this during quantitative
image analysis, we also found no differences in the number of
infiltrating monocytes/macrophages between experimental
groups (Fig. 8h), indicating that the lack of PI3Kd activity in
these cells did not negatively affect their recruitment. Infarct size
(Fig. 8j) was also not different between the experimental groups.
Collectively, these findings suggest that a lack of PI3Kd activity
within CNS-resident cells critically contributes towards the
protective phenotype observed in p110dD910A/D910A mice.
Discussion
In this study we reveal a protective effect afforded by inhibiting
PI3Kd in a murine model of stroke. Our data demonstrate that
genetic or pharmacological inhibition of PI3Kd greatly reduces
TNF secretion from microglia under ischaemia and reperfusion
in vivo or under in vitro GD/restoration. Our data show that
inhibition of PI3Kd up to 3 h post ischaemic stroke has a
significant protective effect, and therefore provides an additional
therapeutic strategy to be considered in this context. Proin-
flammatory cytokines such as TNF, IL-1b and IL-6 play multiple
roles both in the pathology and recovery after ischaemic brain
damage. Microglia activation and TNF release are associated with
cell death and pathological inflammation, but they are also
implicated in immune tolerance and brain repair. Removing TNF
may not be fully beneficial, as this strategy has only had limited
success7,11–14 and TNF-deficient mice appear to have exacerbated
cortical infarction and behavioural deficit41. One of the
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underlying reasons may be that a reduction in the homoeostatic
levels of TNF may affect neuronal survival6,12. Consequently,
approaches designed to dampen TNF release from microglia or to
administer short-lived anti-TNF agents during the acute phase
might prove more effective.
We have previously demonstrated that PI3Kd regulates post-
Golgi trafficking and secretion of TNF in macrophages stimulated
by LPS18. Interestingly, PI3Kd inhibition does not fully abolish
TNF secretion under GD conditions in microglia or after tMCAO
in mice, supporting the existence of two parallel pathways for
TNF secretion: a constitutive low capacity one, independent
of PI3Kd and an inflammation-elicited pathway as previously
described18,42. Difference in cellular sources of TNF might also be
important for controlling TNF levels and effects in the brain.
Astrocytes also produce and release TNF but they are not
sensitive to PI3Kd inhibition in vitro as they do not exhibit PI3Kd
immunoreactivity, suggesting different trafficking regulators
might control TNF release in these cells. The lack of PI3Kd
detection in astrocytes in vitro indicates that the observed
decrease in astrocytic TNF in vivo under I/R may result from
attenuated proinflammatory feedback cascades5,43,44 stemming
from reduced microglial TNF secretion. Our study is in good
agreement with other studies pointing to a key role of microglial
TNF in early-phase inflammation in the CNS13. Our in vitro
studies also highlight the presence of PI3Kd in neurons28 but
their role in TNF secretion could not be tested because secreted
TNF was not detected by our assay in neuronal cultures exposed
to either GD or LPS. The role played by PI3Kd in neurons will
therefore require further investigation.
The TNF-mediated inflammatory response is known to lead to
an increased permeability of the blood–brain barrier5, resulting in
leukocyte infiltration. Such leukocytic recruitment following
experimental stroke has been documented in several species45,46.
Leukocytes are involved in the secondary progression of brain
damage, with a dramatic accumulation of frontline neutrophils
occurring in the infarcted tissue during reperfusion12,42,47, an
observation replicated in our mouse I/R model. Our results reveal
a key role of the PI3Kd-TNF axis in mediating leukocyte
recruitment into the ischaemic brain post reperfusion. TNF can
promote the recruitment and migration of CNS-invading
leukocytes across the vascular endothelial barrier48. Despite this,
the BM chimera experiments carried out in our study reveal that
the reduced level of leukocyte infiltration detected in the absence
of PI3Kd activity is initiated in the CNS, and does not result from
a loss of PI3Kd in circulating leukocytes.
Although the integrity of the blood–brain barrier is known to
be greatly altered by stroke, the access of injected inhibitors to the
brain is uncertain. Here we provide the first method for the
detection of the inhibitor CAL-101 in the brain. Using liquid
chromatography–electrospray ionization–mass spectrometry, we
confirm the presence of CAL-101 in the brain tissue 24 h after
tMCAO. This method is likely to be useful for the detection of
CAL-101 in other tissues and for the treatment of other
conditions.
Taken together, our findings demonstrate that the pharmaco-
logical inhibition of PI3Kd, even post reperfusion, provides
organismal protection against reperfusion-induced inflammation
in ischaemic stroke, leading to significantly improved neuro-
logical outcomes. The efficacy of delayed treatment is highly
relevant in a clinical setting for ischaemic stroke. Drugs
selectively targeting PI3Kd can thus potentially be exploited
alone or in synergy with existing reperfusion approaches to
reduce I/R-induced neuroinflammation. By blocking the intra-
cellular trafficking and secretion of TNF and potentially other
proinflammatory cytokines such as IL-1b and IL-6 in Iba1-
positive cells, PI3Kd inhibition represents an attractive strategy to
control injurious neuroinflammatory responses within an acute
time window in ischaemic stroke.
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Methods
Mice and cerebral focal I/R model. p110dD910A/D910A mice30 and wild-type
littermates bred on a C57BL/6 background were kept under pathogen-free
conditions. Blood glucose and haematocrit analyses in male mice revealed no
differences between genotypes (blood glucose: 12.40±0.9539 versus 11.60±0.2646,
respectively, n¼ 4; haematocrit: 34.38±0.7181 versus 36.50±2.010 n¼ 4), thereby
negating a role of these physiological variables in subsequent stroke outcomes. For
in vivo experiments with CAL-101, wild-type C57BL/6 mice were used. All animal
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experiments were approved by the Institutional Animal Ethics Committee and
conducted in accordance with the Australian Code of Practice for the care and use
of animals for scientific purposes. Mice for all animal experiments were
randomized and coded, so experiments were carried out blindly. Exclusion criteria
were excessive bleeding or death within 24 h after tMCAO. Male, 12- to 22-week-
old, mice were anaesthetized for cerebral focal I/R induction by tMCAO29,33–35.
After a midline neck incision, the left external carotid and pterygopalatine arteries
were isolated and ligated with 5-0 silk thread. The internal carotid artery was
occluded with a clip at the peripheral site of the bifurcation to the pterygopalatine
artery and the common carotid artery was then ligated with 5-0 silk thread. The
external carotid artery was cut and a 6-0 nylon suture with a blunted tip (0.20mm)
was inserted. The clip at the internal carotid artery was then removed for
advancement of the nylon suture into the middle cerebral artery to slightly more
than 6mm from the internal carotid–pterygopalatine artery bifurcation. After 1 h
occlusion, the nylon suture and the ligatures were removed to initiate reperfusion
for 24 h up to 72 h. In the sham group, these arteries were visualized but not
disturbed. For CAL-101 treatment, wild-type C57BL/6 mice were administered
either 40mg kg 1 CAL-101 (Active Biochem, #A-1138) or vehicle
dimethylsulphoxide (Sigma), by 25 ml infusion into the femoral vein, 15min before
I/R (pre-treatment), or 3 and 6 h after initiation of reperfusion (post-treatment).
Controls and animals treated with CAL-101 underwent cerebral blood flow (CBF)
measurements using a laser Doppler perfusion monitor (Moor Lab). The CBF
measurements obtained immediately before and after MCAO and again at 3 h after
reperfusion showed anB90–95% reduction in the blood flow to the MCAO infarct
region, which did not differ between groups.
Generation of BM chimeric mice. Cx3cr1gfp/þ male recipient mice (6–9 months
of age)49 were sublethally irradiated with two doses of 5Gy delivered 14 h apart and
their immune system rescued via BM transplantation from either wild-type
(control) or p110dD910A/D910A donors, 3–4 h after the second dose of irradiation50.
In the latter group, expression of the kinase-dead form of PI3Kd was restricted to
the peripheral immune compartment only, thereby allowing for the assessment of
leukocyte recruitment following ischaemic stroke. BM chimeric mice were let to
recover for 20 weeks before being subjected to tMCAO as detailed above. Blood
analysis confirmed the efficiency of the chimerization protocol, with over 95% of
circulating white blood cells being of donor BM origin. CBF measurements showed
an B80% decrease in the blood flow to the MCAO infarct region, which did not
differ between groups.
Infarct measurement and neurological assessment. Brains from mice eutha-
nized 72 h after I/R were cut into 2mm coronal sections, before staining with 2%
2,3,5-triphenyltetrazolium chloride (Sigma) in PBS (Sigma) at 37 C. Infarct sizes
were determined from digitized images by measuring the area of damaged tissue in
the left (ipsilateral) hemisphere in every section using ImageJ software (version
1.44; NIH) and normalized to the total area of the contralateral hemisphere. After
I/R, each mouse was scored every day until the killing on a five-point system34,35:
0, no neurological deficits; 1, failure to extend right paw; 2, circling to the right;
3, falling to the right; and 4, unable to walk spontaneously.
Tissue sections and immunohistochemistry. Mice were anaesthetized and
transcardially perfused with saline and 10% phosphate-buffered formaldehyde
(Sigma). Whole brains were then fixed in 4% paraformaldehyde (Sigma) overnight
at 4 C before sequentially immersing them into 20 and 30% solutions of sucrose
(w/v) at 4 C. For cryosections, the brains were embedded and frozen in TissueTek
(Sakura) before being sectioned in the coronal anatomical plane into 10 mm sec-
tions using a Microm HM560MV cryostat (Thermo Scientific) and mounted onto
glass slides. For antigen retrieval of Iba1 and TNF, sections were treated with
20mgml 1 proteinase K (Roche) in 10mM Tris–HCl (Sigma), pH 7.4. Selected
sections were incubated for 1 h in blocking buffer (PBS containing 10% fetal bovine
serum (FBS; Life Technologies) and 0.1% Triton X-100 (Sigma)) before primary
incubation for 1.5 h with goat anti-Iba1 (Abcam ab5076, 1:100) or rabbit anti-
GFAP (Abcam ab7260, 1:500) and mouse anti-TNF (Abcam ab1793, 1:100) diluted
in PBS. After washes in 0.1% Triton X-100/PBS for 15min, the sections were
incubated for 1 h with Alexa Fluor488 rabbit anti-goat IgG and Alexa Fluor568
rabbit anti-mouse IgG, or Alexa Fluor568 goat anti-rabbit and Alexa Fluor488 goat
anti-mouse (all from Invitrogen, 1:500) diluted in blocking buffer. All incubations
were performed at room temperature. After washes in 0.1% Triton X-100/PBS, the
slides were counterstained with 40 ,6-diamidino-2-phenylindole and mounted in
Vectashield (Vector Laboratories). Z-series through the coronal sections, 5–9.8 mm
in the infarct or penumbra regions to 9.8 mm in the contralateral regions were
captured on an inverted confocal microscope (LSM510; Carl Zeiss) with a  20
(numerical aperture 0.75) objective using the associated ZEN software. LSM images
were analysed in Imaris Coloc (version 7.2.3; Bitplane) and Pearson’s correlation
coefficient (r) values were calculated to measure the correlation dependency of co-
localized voxels in three dimension between separate colour channels37,38. For
experiments in BM chimeric mice, brains were cut into 40 mm coronal sections
with a microtome (1:4 series) and subjected to free-floating immunofluorescence
staining. Mouse anti-MAP-2 (Millipore MAB3418, 1:1,000) staining was used to
determine infarct size. For this, an average of 15 free-floating sections were stained
per brain and imaged using a Zeiss fluorescence slide scanner, after which infarct
sizes were determined by measuring the area of damaged (that is, MAP-2 negative)
tissue in the ipsilateral hemisphere, normalizing it to the total area of the
contralateral hemisphere. For quantitative assessment of neutrophils as well as
infiltrating and microglia-derived macrophage numbers, a separate series of
sections was stained with rat anti-Ly6B.2 (AbD Serotec MCA771GA, 1:400) and
goat anti-Iba1 (Abcam ab5076, 1:100). Ly6B.2þ Iba1 neutrophils were counted
under the  20 objective; the number of infiltrating donor BM-derived
macrophages was determined by counting the number of Iba1þGFP cells on
images taken under the  10 objective of a Zeiss microscope using ApoTome.
Immunocytochemistry. Neurons or glial cells cultured on coverslips were fixed in
4% paraformaldehyde for staining18. Washes were performed in PBS with or
without BSA (Sigma) for blocking. Cells were permeabilized in 0.1% Triton X-100/
PBS for 5min before incubation for 1 h with rabbit anti-PI3Kd antibody (Abcam
ab1678, 1:400)51 and mouse anti-bIII-tubulin (Covance MMS-435P, 1:1,000), goat
anti-Iba1 (Abcam ab5076, 1:500) or chicken anti-GFAP (Abcam ab4674, 1:1,000),
followed by incubation for 40min with Cy3-conjugated donkey anti-rabbit
antibody and Alexa Fluor488-conjugated donkey anti-mouse, anti-goat or anti-
chicken antibody (Invitrogen, 1:500). All antibodies were diluted in blocking buffer.
Coverslips were mounted in ProLong gold reagent (Invitrogen). Confocal images
were acquired on the LSM510 microscope with a  63 (numerical aperture 1.4)
objective using the ZEN software.
Western blotting. Whole brains removed from perfused mice 24 h after I/R were
immediately dissected into two hemispheres and homogenized in ice-cold tissue
buffer (Thermo Scientific) containing protease and phosphatase inhibitors (Roche)
before centrifugation at 14,000 r.p.m. for 10min at 4 C. The supernatants were
then assessed for protein concentration (Bradford assay; Bio-Rad Laboratories),
before SDS–polyacrylamide gel electrophoretic protein separation on 10% acryla-
mide gels. The proteins were transferred to nitrocellulose membranes and incu-
bated with the different antibodies according to the manufacturer’s instructions
(TNF, Calbiochem #654300, 1:1,000; IL-1b, Abcam ab5076, 1:500; IL-6, AbD
Serotec #AAM15G, 1:500). The membranes were washed, incubated with horse-
radish peroxidase-conjugated secondary antibodies for 2 h, washed and then
exposed to substrate for enhanced chemiluminescence (Pierce Endogen, USA) for
2min. The signals were visualized using X-ray films (Fujifilm Corporation, Tokyo,
Japan). The films were scanned and densitometric analysis was carried out with
NIH Image J software. Alternatively, the membranes were incubated with goat
anti-rabbit DyLight 800 or goat anti-mouse DyLight 680B (both 1:10,000) and
scanned using the Odyssey Infrared Imaging System (LI-COR Biosciences).
Primary cortical neurons, astrocytes or microglia. Brain cortices were removed
from embryonic day 18 mouse embryos (for neuronal cultures) or postnatal day 1
mice (for astrocytes or microglia cultures)34. The cortical tissue was incubated in
Ca2þ -/Mg2þ -free Hank’s balanced salt solution (Thermo Scientific) containing
1mgml 1 trypsin (Sigma) for 10min at 37 C. The dissociated tissue was then
passed through culture medium, which was either Neurobasal medium (Life
Technologies) supplemented with B-27 (Life Technologies) and 1% L-glutamine
(v/v) for neuronal enrichment, or DMEM (Life Technologies) containing 50% F12
(v/v; Life Technologies), 10% heat-inactivated FBS (Life Technologies) and 1%
L-glutamine for glial enrichment. Cells were dissociated by trituration and seeded
in either Neurobasal/B-27/L-glutamine or DMEM:F12/FCS/L-glutamine medium at
densities from 105 cellsml 1 (for neurons) to 1.5 106 cellsml 1 (for glia)52. All
cells were maintained at 37 C in humidified 5% CO2/95% air. Neurons were
cultured for 7 days before experiments, whereas glia-enriched cultures were
maintained for 20–25 days, with the medium being replaced every 3–5 days. To
harvest microglia, 490% confluent glia cultures were rinsed with FBS-free
DMEM:F12 and incubated with 0.05% trypsin for 20min. Microglia remained
adherent, whereas other glial types lifted away52. To harvest astrocytes,
470% confluent glia cultures were incubated with 0.25% trypsin for 2min.
Astrocytes were harvested from supernatants. All cells were then plated for
experiments.
Cell treatments. For LPS stimulation, astrocytes or microglia were incubated with
100 ngml 1 LPS (from Salmonella minnesota Re595; Sigma). For GD experiments,
glucose-free Locke’s buffer containing 154mM NaCl, 5.6mM KCl, 2.3mM CaCl2,
1mM MgCl2, 3.6mM NaHCO3 and 5mM HEPES, pH 7.2, was used. For drug
treatments, cells were incubated with IC87114 (Symansis), CAL-101 (Active Bio-
chem, #A-1138) and LPS, glucose-free Locke’s buffer (GD), or a combination
thereof. For TNF surface delivery assay18,32, TNF-converting enzyme inhibitor was
added at the same time as LPS or included in the glucose-free Locke’s buffer (GD).
All inhibitors were reconstituted in dimethylsulphoxide (Sigma) with final
concentrations o0.1% in assays.
Assaying TNF secretion. To determine the levels of secreted TNF, a commercial
BD OptEIA TNF Elisa Set II (#558534) kit (BD Biosciences) was used to quantify
cytokine concentration in samples according to the manufacturer’s instructions.
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Tandem mass spectrometry. Whole-brain samples (ca. 500mg) were homo-
genized in a tissue blender (2min) in ice-cold 0.32M sucrose (5ml). Brain
homogenate (100 ml) or plasma (10 ml) was extracted in 10 volumes of acetonitrile/
formic acid (99:1, v/v), and centrifuged (13,000 g, 15min, 4 C) to remove pre-
cipitated proteins. The clear supernatant was decanted and diluted 1/10 with 2%
formic acid (v/v). Sample clean-up was achieved using cation-exchange solid-phase
extraction cartridges (Waters Oasis MCX 30 mm 10mg 1 cc), which provided
excellent recoveries (495% from brain and 499% plasma). The cartridges were
pre-conditioned with methanol (1ml) followed by water (1ml), and then loaded
with the diluted extracts by gravity, and subsequently washed with 2% formic acid
(v/v), followed by methanol (1ml). CAL-101 was eluted using 1ml of 5%
ammonium hydroxide in methanol (v/v). The samples were evaporated using a
vacuum concentrator (37 C, 2 h) and reconstituted in acetonitrile/water 1:1 (50 ml,
v/v) containing reserpine (0.05 mM, internal standard). CAL-101 levels were
measured by tandem mass spectrometry on a 5500 QTRAP mass spectrometer
with TurboV ion source (AB Sciex), connected to a Nexera UHPLC (Shimadzu).
Data acquisition and analysis was performed using AB Sciex Analyst 1.5.2 software.
The instrument was operated in the positive ion mode under multiple reaction
monitoring conditions (m/z 416.24176.0 for CAL-101, and m/z 609.24195.1 for
reserpine) using the following parameters: gas heater temperature (400 C), elec-
trospray gas (20 psi), curtain gas (30 psi), ion spray voltage (5,000V), declustering
potential (80 V), collision energy (45V) and cell exit potential (10 V). CAL-101 and
reserpine eluted at 0.7min using a linear gradient increasing from 50 to 90% A at
400ml min 1 over 4min (HILIC Kinetex column, 75 2.1mm2, 2.6 mm, from
Phenomenex), using 0.1% formic acid as buffer A, and acetonitrile/water 9:1 (v/v)
with 0.1% formic acid as solvent B (injection volume, 5 ml). The lower limits of
quantification (as defined by signal/noise ratioZ10) for CAL-101 were 1 nmol l 1
(plasma, coefficient of variation (CV) 3%, n¼ 3) and 10 pmol g 1 (brain,
CV 4%, n¼ 3).
Flow cytometry. Animals were euthanized and perfused with PBS. Brains were
dissected, cerebella were removed and left ischaemic (ipsilesional) hemispheres
were selected. Three hemispheres were pooled, digested for 30min at 37 C
(1mgml 1 collagenase, 0.1 mgml 1 DNAseI in DMEM) and pressed through a
cell strainer (40 mm; BD Biosciences). Cells were incubated with standard ery-
throcyte lysis buffer on ice, separated from myelin and debris by Percoll gradient
(GE Healthcare #17-5445-01) centrifugation, and incubated with the following
antibody cocktail for 30min at room temperature in fluorescence-activated cell
sorter buffer (0.5% BSA, 0.02% sodium azide in PBS)—CD45 (30-F11, eBioscience
#25-0451-82, 1:100), Ly6G (1A8, BD Biosciences #560603, 1:100), CD11b (M1/70,
BD #557396, 1:300)33. Data were acquired with a LSR II FACS system (BD
Biosciences) and analysed with FlowJo (TreeStar). Doublets were excluded with
forward scatter (FSC)-A and FSC-H linearity.
Statistical analysis. Statistical analysis was performed by Student’s t-test or by
one-way analysis of variance and Turkey’s post hoc test, as indicated, using Prism
software (version 5; GraphPad Software). The sample sizes were chosen based on
previous experience and published reports18,34,35. Differences between groups were
considered significant at Po0.05.
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